Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in ...
Rigel Pharmaceuticals, Inc. is a biotechnology company headquartered in South San Francisco, California, incorporated in 1996. The company focuses on developing and commercializing small molecule drugs for hematologic disorders and cancer. Its primary commercial products include TAVALISSE (fostamatinib disodium hexahydrate) for chronic immune thrombocytopenia (ITP), REZLIDHIA (olutasidenib) for relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation, and GAVRETO (pralsetinib) for RET fusion-positive non-small cell lung cancer and thyroid cancer. Rigel also has a pipeline including R289, an IRAK1/4 inhibitor in Phase 1b for lower-risk myelodysplastic syndrome and other conditions. The company collaborates with MD Anderson Cancer Center and the CONNECT network for clinical development. Financially, Rigel has shown strong performance with a market cap of $743 million, a TTM net profit margin of 116.3%, and a price-to-earnings ratio of 2.27. Key financial metrics indicate a solid balance sheet with low debt-to-equity (0.094) and strong liquidity (current ratio 1.946). The company employs 172 full-time staff as of the latest data. Leadership includes CEO Raul R. Rodriguez, who has been in the role since 2014. Rigel is committed to improving patient lives through innovative therapies, with a focus on underserved hematologic and oncologic conditions.
